» Articles » PMID: 23699601

Mutational and Structural Analysis of Diffuse Large B-cell Lymphoma Using Whole-genome Sequencing

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous cancer composed of at least 2 molecular subtypes that differ in gene expression and distribution of mutations. Recently, application of genome/exome sequencing and RNA-seq to DLBCL has revealed numerous genes that are recurrent targets of somatic point mutation in this disease. Here we provide a whole-genome-sequencing-based perspective of DLBCL mutational complexity by characterizing 40 de novo DLBCL cases and 13 DLBCL cell lines and combining these data with DNA copy number analysis and RNA-seq from an extended cohort of 96 cases. Our analysis identified widespread genomic rearrangements including evidence for chromothripsis as well as the presence of known and novel fusion transcripts. We uncovered new gene targets of recurrent somatic point mutations and genes that are targeted by focal somatic deletions in this disease. We highlight the recurrence of germinal center B-cell-restricted mutations affecting genes that encode the S1P receptor and 2 small GTPases (GNA13 and GNAI2) that together converge on regulation of B-cell homing. We further analyzed our data to approximate the relative temporal order in which some recurrent mutations were acquired and demonstrate that ongoing acquisition of mutations and intratumoral clonal heterogeneity are common features of DLBCL. This study further improves our understanding of the processes and pathways involved in lymphomagenesis, and some of the pathways mutated here may indicate new avenues for therapeutic intervention.

Citing Articles

Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers.

Najia M, Jha D, Zhang C, Laurent B, Kubaczka C, Markel A bioRxiv. 2025; .

PMID: 39975048 PMC: 11838449. DOI: 10.1101/2025.01.31.635709.


Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells.

Jin F, He L, Chen Y, Tian W, Liu L, Ge L Braz J Med Biol Res. 2024; 57:e13278.

PMID: 39383379 PMC: 11463907. DOI: 10.1590/1414-431X2024e13278.


SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma.

Portelinha A, Wang S, Parsa S, Jiang M, Gorelick A, Mohanty S J Exp Med. 2024; 221(10).

PMID: 39235528 PMC: 11380151. DOI: 10.1084/jem.20231143.


Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH-BCL2.

Collinge B, Ben-Neriah S, Hilton L, Alduaij W, Tucker T, Slack G Blood. 2024; 144(15):1611-1616.

PMID: 39133931 PMC: 11487639. DOI: 10.1182/blood.2024025603.


Advances in biology, diagnosis and treatment of DLBCL.

Shi Y, Xu Y, Shen H, Jin J, Tong H, Xie W Ann Hematol. 2024; 103(9):3315-3334.

PMID: 39017945 PMC: 11358236. DOI: 10.1007/s00277-024-05880-z.


References
1.
Siegert J, Rushton J, Sellers W, Kaelin Jr W, Robbins P . Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity. Oncogene. 2000; 19(50):5703-11. DOI: 10.1038/sj.onc.1203966. View

2.
Greenman C, Pleasance E, Newman S, Yang F, Fu B, Nik-Zainal S . Estimation of rearrangement phylogeny for cancer genomes. Genome Res. 2011; 22(2):346-61. PMC: 3266042. DOI: 10.1101/gr.118414.110. View

3.
Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B . Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012; 44(12):1316-20. DOI: 10.1038/ng.2469. View

4.
Cai X, Liu X . Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage. Proc Natl Acad Sci U S A. 2008; 105(44):16958-63. PMC: 2579360. DOI: 10.1073/pnas.0804608105. View

5.
Cattoretti G, Mandelbaum J, Lee N, Chaves A, Mahler A, Chadburn A . Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res. 2009; 69(22):8686-92. PMC: 2973841. DOI: 10.1158/0008-5472.CAN-09-1110. View